Last reviewed · How we verify

NCT04435756

A Study of miRNA 371 in Patients With Germ Cell Tumors

Active, enrolled Last updated 12 March 2026
What this trial tests

trial testing Biomarker Analysis in Germ Cell Tumor in 956 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
28 July 2020
Primary endpoint
1 January 2027
1 January 2028

Quick facts

Lead sponsorSWOG Cancer Research Network
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment956
Start date28 July 2020
Primary completion1 January 2027
Estimated completion1 January 2028
Sites424 locations across Canada, United States, Guam

Drugs / interventions tested

Conditions studied

Sponsor

SWOG Cancer Research Network

Who can join

18 and older, any sex, with Germ Cell Tumor or Metachronous Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. microRNA-based diagnostic and therapeutic applications in cancer medicine.
    Sempere LF, Azmi AS, Moore A. · · 2021 · cited 97× · PMID 33998154 · DOI 10.1002/wrna.1662
  2. Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
    Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027
  3. The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role.
    Zuo J, Zhang Z, Li M, Yang Y, et al · · 2022 · cited 43× · PMID 35081965 · DOI 10.1186/s12943-021-01488-3
  4. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
    Fankhauser CD, Christiansen AJ, Rothermundt C, Cathomas R, et al · · 2022 · cited 34× · PMID 34912073 · DOI 10.1038/s41416-021-01643-z
  5. DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients.
    Sequeira JP, Lobo J, Constâncio V, Brito-Rocha T, et al · · 2022 · cited 20× · PMID 35756620 · DOI 10.3389/fonc.2022.876732
  6. Liquid Biopsies in the Clinical Management of Germ Cell Tumor Patients: State-of-the-Art and Future Directions.
    Lobo J, Leão R, Jerónimo C, Henrique R. · · 2021 · cited 18× · PMID 33800799 · DOI 10.3390/ijms22052654
  7. Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors.
    Sykes J, Kaldany A, Jang TL. · · 2024 · cited 10× · PMID 39685906 · DOI 10.3390/jcm13237448
  8. Recent advances in testicular germ cell tumours.
    Mele T, Reid A, Huddart R. · · 2021 · cited 10× · PMID 34557871 · DOI 10.12703/r/10-67

Verify or expand the search:

Other trials of Biomarker Analysis

Trials testing the same drug.

Other recruiting trials for Germ Cell Tumor

Currently open trials in the same condition.

Other SWOG Cancer Research Network trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04435756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing